Target expression details
| Target General Information | |||||
|---|---|---|---|---|---|
| Target ID | T73475 | ||||
| Target Name | Matrix metalloproteinase-7 | ||||
| Synonyms | MMP-7; Matrin; Matrix metalloproteinase-7; Pump-1 protease; Uterine metalloproteinase; MMP7 | ||||
| Target Type | Successful | ||||
| Gene Name | MMP7 | ||||
| Biochemical Class | Peptidase | ||||
| UniProt ID | MMP7_HUMAN | ||||
| Target Gene Expression Profiles in the Disease-Relevant Drug Targeted Tissue of the Patients and Healthy Individuals | |||||
| Disease | Lung cancer | ||||
| Example drug | Prinomastat | Approved | [1], [2], [3] | ||
| Tissue | Lung tissue | ||||
| Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual | Fold-change: 0.96 Z-score: 0.80 P-value: 6.83E-17 |
||||
| Level of differential expression between the patients in the disease section of the tissue and the patients in the normal section of the tissue adjacent to the disease section | Fold-change: 1.28 Z-score: 1.30 P-value: 1.80E-19 |
||||
|
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles of the patients in the normal section of the tissue adjacent to the disease section
Target gene expression profiles in the tissue of healthy individual
|
|||||
| Disease | Prostate cancer | ||||
| Example drug | Prinomastat | Approved | [1], [2], [3] | ||
| Tissue | Prostate | ||||
| Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual | Fold-change: -0.19 Z-score: -0.09 P-value: 4.44E-01 |
||||
|
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
|
|||||
| Disease | Sarcoma | ||||
| Example drug | BMS 275291 | Discontinued in Phase 3 | [4], [3] | ||
| Tissue | Muscle tissue | ||||
| Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual | Fold-change: -0.20 Z-score: -0.57 P-value: 4.87E-01 |
||||
| Level of differential expression between the patients in the disease section of the tissue and the patients in the normal section of the tissue adjacent to the disease section | Fold-change: 0.21 Z-score: 0.96 P-value: 2.89E-02 |
||||
|
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles of the patients in the normal section of the tissue adjacent to the disease section
Target gene expression profiles in the tissue of healthy individual
|
|||||
| Target Gene Expression Profiles in Other Tissues of Healthy Individuals | |||||
|
|||||
| Reference | |||||
| REF 1 | Emerging therapies for neuropathic pain. Expert Opin Emerg Drugs. 2005 Feb;10(1):95-108. | ||||
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6505). | ||||
| REF 3 | NCBI GEO: archive for functional genomics data sets--update. | ||||
| REF 4 | Phase 1/2 trial of BMS-275291 in patients with human immunodeficiency virus-related Kaposi sarcoma: a multicenter trial of the AIDS Malignancy Consortium. Cancer. 2008 Mar 1;112(5):1083-8. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.